Abstract:Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is causing an unprecedented global pandemic demanding the urgent development of therapeutic strategies. Microarray binding experiments, using an extensive heparan sulfate (HS) oligosaccharide library, showed that the receptor binding domain (RBD) of the spike of SARS-CoV-2 can bind HS in a length- and sequence-dependent manner. A hexasaccharide composed of IdoA2S-GlcNS6S repeating units was identified as the minimal binding epitope. Surface plasmon resonance showed the SARS-CoV-2 spike protein binds with a much higher affinity to heparin (KD = 55 nM) compared to the RBD (KD = 1 μM) alone. It was also found that heparin does not interfere in angiotensin-converting enzyme 2 (ACE2) binding or proteolytic processing of the spike. However, exogenous administered heparin or a highly sulfated HS oligosaccharide inhibited RBD binding to cells. Furthermore, an enzymatic removal of HS proteoglycan from physiological relevant tissue resulted in a loss of RBD binding. The data support a model in which HS functions as the point of initial attachment allowing the virus to travel through the glycocalyx by low-affinity high-avidity interactions to reach the cell membrane, where it can engage with ACE2 for cell entry. Microarray binding experiments showed that ACE2 and HS can simultaneously engage with the RBD, and it is likely no dissociation between HS and RBD is required for binding to ACE2. The results highlight the potential of using HS oligosaccharides as a starting material for therapeutic agent development.Various methods demonstrate that the RBD of SARS-CoV-2 spike can bind to heparan sulfate (HS) in a sequence-dependent manner supporting a model in which HS functions as the initial attachment point.This article has not yet been cited by other publications.

Regulation Mechanism for the Binding Between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II.

A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2

A hydrophobic-interaction-based mechanism trigger docking between the SARS CoV 2 spike and angiotensin-converting enzyme 2

Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2

SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets

Two-Stage Recognition Mechanism of the SARS-CoV-2 Receptor-Binding Domain to Angiotensin-Converting Enzyme-2 (ACE2)

Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues

The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming

Activation Pathways and Free Energy Landscapes of the SARS-CoV-2 Spike Protein

Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation

Computational Simulations Reveal the Binding Dynamics Between Human ACE2 and the Receptor Binding Domain of SARS-CoV-2 Spike Protein

Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions

Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid

Computational Analysis of the SARS-CoV-2 RBD–ACE2-Binding Process Based on MD and the 3D-RISM Theory

Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2